Cargando…

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danilovic, Debora L. S., Castro, Gilberto, Roitberg, Felipe S. R., Vanderlei, Felipe A. B., Bonani, Fernanda A., Freitas, Ricardo M. C., Coura-Filho, George B., Camargo, Rosalinda Y., Kulcsar, Marco A., Marui, Suemi, Hoff, Ana O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118781/ https://www.ncbi.nlm.nih.gov/pubmed/29791660 http://dx.doi.org/10.20945/2359-3997000000046

Ejemplares similares

Diagnostic performance of thyroid ultrasound in Hürthle cell carcinomas
por: Santana, Nathalie Oliveira, et al.
Publicado: (2019)

Critical analysis of molecular tests in indeterminate thyroid nodules
por: Danilovic, Debora L. S., et al.
Publicado: (2018)

SAT-614 False-Positive in Measurement of Thyroglobulin in a Patient with Mixed Connective Tissue Disease
por: Maciel, Ana Alice, et al.
Publicado: (2019)

25-Hydroxyvitamin D and TSH as Risk Factors or Prognostic Markers in Thyroid Carcinoma
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2016)

Thymic hyperplasia in Graves' disease
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

SAT-567 Mutational Profile of Hurthle Cell Carcinomas: Recurrent Mutations in Wnt/β-catenin Pathway Genes
por: Santana, Nathalie, et al.
Publicado: (2019)

Evaluation of Downstream Regulatory Element Antagonistic Modulator Gene in Human Multinodular Goiter
por: Shinzato, Amanda, et al.
Publicado: (2015)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

Thyroid collision tumor containing oncocytic carcinoma, classical and hobnail variants of papillary carcinoma and areas of poorly differentiated carcinoma
por: Toyoshima, Marcos Tadashi Kakitani, et al.
Publicado: (2021)

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis
por: Burney, Ikram A., et al.
Publicado: (2021)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
por: Leung, Henry W. C., et al.
Publicado: (2016)

Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma
por: Takano, Michitoshi, et al.
Publicado: (2016)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Active surveillance of papillary thyroid microcarcinomas in South America: Are we ready?
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2019)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
por: Chen, Yen-Yang, et al.
Publicado: (2020)

Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)

Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System
por: Aguiar, Pedro, et al.
Publicado: (2020)

THU587 High Prevalence Of Primary Aldosteronism Diagnosis In Patients With Papillary Thyroid Cancer And Hypertension: A Cross-sectional Case-control Study
por: Ana Wolf, Ana Alice Wolf Maciel, et al.
Publicado: (2023)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
por: Wan, Xuying, et al.
Publicado: (2016)

Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study
por: Luo, Xiangji, et al.
Publicado: (2016)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Erratum to “Durable Objective Response to Sorafenib and Role of Sequential Treatment in Unresectable Hepatocellular Carcinoma”
Publicado: (2022)

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
por: Li, Xiaomi, et al.
Publicado: (2022)

Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States
por: Li, Daneng, et al.
Publicado: (2023)

Editorial Comment: Classification of the renal papillary abnormalities by flexible ureteroscopy: evaluation of the 2016 version and update
por: Danilovic, Alexandre
Publicado: (2021)

Editorial Comment: TClassification of the renal papillary abnormalities by flexible ureteroscopy: evaluation of the 2016 version and update
por: Danilovic, Alexandre
Publicado: (2022)

Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
por: Devata, Sumana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i6gibgcb9urqeu23vu1ala1qgb